Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quince Therapeutics, Inc. - Common Stock (NQ:QNCX)

0.5471 +0.4171 (+320.85%)
Streaming Delayed Price Updated: 3:14 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,335,934,643
Open 0.2834
Bid (Size) 0.5470 (700)
Ask (Size) 0.5471 (33,500)
Prev. Close 0.1300
Today's Range 0.2459 - 0.6520
52wk Range 0.1251 - 4.550
Shares Outstanding 36,382,989
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks are making the most noise in today's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill

Performance

YTD
-81.8%
-81.8%
1 Month
-81.5%
-81.5%
3 Month
-65.8%
-65.8%
6 Month
-65.8%
-65.8%
1 Year
-61.7%
-61.7%

More News

Read More
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? ↗
Via Stocktwits
News headline image
Why Is Quince Therapeutics Stock Soaring Tuesday? ↗
Via Benzinga
Monday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
From Quince Therapeutics, Inc.
Via Business Wire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Why Did QNCX Stock Plummet Over 90% Today? ↗
Via Stocktwits
Topics Bankruptcy
News headline image
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Wednesday's session: top gainers and losers ↗
Via Chartmill
News headline image
Which stocks are moving on Wednesday? ↗
Via Chartmill
News headline image
Quince Therapeutics to Participate at Investor Events in December 2025
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Quince Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Quince Therapeutics, Inc. - Common Stock publicly traded?
Yes, Quince Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Quince Therapeutics, Inc. - Common Stock trade on?
Quince Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Quince Therapeutics, Inc. - Common Stock?
The ticker symbol for Quince Therapeutics, Inc. - Common Stock is QNCX on the Nasdaq Stock Market
What is the current price of Quince Therapeutics, Inc. - Common Stock?
The current price of Quince Therapeutics, Inc. - Common Stock is 0.5471
When was Quince Therapeutics, Inc. - Common Stock last traded?
The last trade of Quince Therapeutics, Inc. - Common Stock was at 02/10/26 03:14 PM ET
What is the market capitalization of Quince Therapeutics, Inc. - Common Stock?
The market capitalization of Quince Therapeutics, Inc. - Common Stock is 19.91M
How many shares of Quince Therapeutics, Inc. - Common Stock are outstanding?
Quince Therapeutics, Inc. - Common Stock has 20M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.